China's COVID-19 vaccines based on the inactivated virus can be upgraded to cope with new variants in about two months, as reported in the National Post
The claims were made in the Global Times on Tuesday, citing an expert with the Chinese Center for Disease Control and Prevention (CDC).
Vaccines from Sinovac and Sinopharm's China National Pharmaceutical Group, which are being used in China and overseas, contain the inactivated SARS-CoV-2 virus that cannot replicate in human cells.
If necessary, an upgrade for China's inactivated COVID-19 vaccine could be completed in about two months, Shao Yiming, a scientist with China CDC, told the Global Times.
The neutralizing ability of antibodies induced by Chinese vaccines appeared weaker against recently discovered variants in the UK and South Africa, the Global Times quoted Shao as saying, citing studies by Chinese vaccine companies and labs.
According to Shao, the redesign of inactivated COVID-19 vaccines could take longer than for vaccines based on mRNA technology, which does not require cultivating and inactivating the virus.
To read more NewsPoints articles, click here.